CLSD Clearside: Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan

Clearside Biomedical (CLSD) business relies on stable demand in ophthalmology, which remains independent of economic downturns. The company possesses exclusive technology for targeted drug delivery via microneedles, creating a robust barrier for major players. However, R&D costs and payment timelines from counterparties create certain pressure. This price chart featuring the 0.00 metric visualizes the asset's current state.

Clearside - Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan CLSD (periode 23.11.2025 - 13.12.2025)

Ringkesan rincian data analitis clearsidebio.com (CLSD)

- rega saiki lan proyeksi nilai saham:

Rega saham Clearside|CLSD - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Biji pasar Clearside Corp|CLSD - Total Nilai Perusahaan

- rincian valuasi buku bisnis:

Nilai Buku saben Saham Clearside Biomedical|CLSD - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku clearsidebio.com|CLSD - Gunggung Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Clearside Biomedical|CLSD - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Clearside Biomedical, Inc.|CLSD - Utang perusahaan|Utang-utang marang kapitalisasi buku Clearside Corp|CLSD - Utang jangka dawa|Utang jangka cendhak perusahaan Clearside Biomedical|Likuiditas cepet clearsidebio.com

- rincian asil keuangan lan kelipatan valuasi:

CLSD - Bathi pungkasan|Bathi sing dikarepake Clearside Biomedical|CLSD - Periode bali modal bisnis|Pangali Forward P/E Clearside Biomedical|CLSD - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali EV/EBITDA Clearside Corp|CLSD - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) Clearside Biomedical|CLSD - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan clearsidebio.com|CLSD - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Clearside Biomedical

Ringkesan analitik perusahaan:Clearside CLSD

Sampel barang Clearside Biomedical, Inc.

The EV/EBITDA multiple compares the total enterprise value, including net debt, with operating profit before interest, taxes, depreciation, and amortization, allowing for an assessment of the real value of assets regardless of the financing structure. Analyzing the business valuation level via EV/EBITDA helps determine if an asset is overvalued, which is critical for Clearside Biomedical (CLSD), whose microinjection patents create a unique market barrier and drive long-term capitalization.

Analisis pesaing